Literature DB >> 3398530

Structure-activity relationships of the inhibition of human placental aromatase by imidazole drugs including ketoconazole.

M Ayub1, M J Levell.   

Abstract

The aim of the present study was to investigate the effectiveness of several imidazole drugs to inhibit human placental aromatase compared with the known inhibitors of aromatase, 4-hydroxyandrostenedione (4-OHA) and aminoglutethimide (AG). Inhibition was similar with both androstenedione and testosterone as substrates. The order of decreasing inhibitory effect (determined from ID50 values) was: 4-OHA greater than tioconazole greater than econazole greater than bifonazole greater than clotrimazole greater than micomazole greater than isoconazole greater than ketoconazole greater than AG greater than nimorazole. The imidazole drugs and AG were reversible inhibitors of aromatase activity, in contrast 4-OHA was an irreversible inhibitor. Astemizole inhibited less than 40% whereas metronidazole, carbimazole, mebendazole, tinidazole and thiabendazole inhibited less than 20% of aromatase activity at 100 mumol/l. The imidazole drugs and AG were without effect on 3 beta-hydroxysteroid dehydrogenase-isomerase (3 beta-HSD-I) and 17 beta-hydroxysteroid oxidoreductase activity. In contrast 4-OHA was found to be a potent, reversible inhibitor of 3 beta-HSD-I with an ID50 value of 2.15 mumol/l. A common structural feature of the imidazole drugs having an inhibitory effect was the presence of one or more aromatic rings on the N-1 substituent. In contrast, the imidazole drugs having the imidazole ring fused to a benzene ring, i.e. benzimidazoles (astemizole, mebendazole, thiabendazole) and those having an aliphatic side chain on the N-1 of the imidazole ring (carbimazole, metronidazole, nimorazole, tinidazole) were only weak inhibitors of aromatase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3398530     DOI: 10.1016/0022-4731(88)90207-5

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  11 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

Review 3.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

4.  Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens.

Authors:  Andrew G Warrilow; Josie E Parker; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

5.  Clotrimazole inhibits the recombinant human cardiac L-type Ca2+ channel alpha 1C subunit.

Authors:  I M Fearon; S G Ball; C Peers
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  Cytochrome P-450 may link intracellular Ca2+ stores with plasma membrane Ca2+ influx.

Authors:  J Alvarez; M Montero; J García-Sancho
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

7.  The antifungal antibiotic clotrimazole potently inhibits L-type calcium current in guinea-pig ventricular myocytes.

Authors:  G P Thomas; M Karmazyn; A C Zygmunt; C Antzelevitch; N Narayanan
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 8.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

9.  AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor.

Authors:  Shiuan Chen; Dujin Zhou; Li-Yu Hsin; Noriko Kanaya; Cynthie Wong; Richard Yip; Srilatha Sakamuru; Menghang Xia; Yate-Ching Yuan; Kristine Witt; Christina Teng
Journal:  Toxicol Sci       Date:  2014-02-04       Impact factor: 4.849

10.  Selective inhibition of steroidogenic enzymes by ketoconazole in rat ovary cells.

Authors:  Michael Gal; Joseph Orly
Journal:  Clin Med Insights Reprod Health       Date:  2014-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.